Haemonetics

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Haemonetics and other ETFs, options, and stocks.

About HAE

Haemonetics Corp. engages in the development and distribution of hematology products and solutions. It operates through the following segments: Plasma, Blood Center, and Hospital. 

CEO
Christopher A. Simon
CEOChristopher A. Simon
Employees
3,023
Employees3,023
Headquarters
Boston, Massachusetts
HeadquartersBoston, Massachusetts
Founded
1971
Founded1971
Employees
3,023
Employees3,023

HAE Key Statistics

Market cap
3.41B
Market cap3.41B
Price-Earnings ratio
20.48
Price-Earnings ratio20.48
Dividend yield
Dividend yield
Average volume
896.00K
Average volume896.00K
High today
$70.99
High today$70.99
Low today
$66.82
Low today$66.82
Open price
$67.49
Open price$67.49
Volume
148.48K
Volume148.48K
52 Week high
$94.99
52 Week high$94.99
52 Week low
$47.32
52 Week low$47.32

Stock Snapshot

As of today, Haemonetics(HAE) shares are valued at $70.76. The company's market cap stands at 3.41B, with a P/E ratio of 20.48.

On 2025-11-07, Haemonetics(HAE) stock traded between a low of $66.82 and a high of $70.99. Shares are currently priced at $70.76, which is +5.9% above the low and -0.3% below the high.

Haemonetics(HAE) shares are trading with a volume of 148.48K, against a daily average of 896K.

In the last year, Haemonetics(HAE) shares hit a 52-week high of $94.99 and a 52-week low of $47.32.

In the last year, Haemonetics(HAE) shares hit a 52-week high of $94.99 and a 52-week low of $47.32.

HAE News

TipRanks 21m
Haemonetics upgraded to Neutral from Underperform at BofA

BofA upgraded Haemonetics (HAE) to Neutral from Underperform with a price target of $75, up from $58. Plasma volume growth returned to high single digits in the...

Simply Wall St 5h
A Piece Of The Puzzle Missing From Haemonetics Corporation's 36% Share Price Climb

Haemonetics Corporation ( ) shares have had a really impressive month, gaining 36% after a shaky period beforehand. Unfortunately, the gains of the last month d...

A Piece Of The Puzzle Missing From Haemonetics Corporation's 36% Share Price Climb
Seeking Alpha 6h
Haemonetics raises 2026 guidance, projects 7%–10% organic growth ex CSL amid strong plasma and hospital performance

Earnings Call Insights Haemonetics raises 2026 guidance, projects 7%–10% organic growth ex CSL amid strong plasma and hospital performance Nov. 07, 2025 3:27 AM...

Haemonetics raises 2026 guidance, projects 7%–10% organic growth ex CSL amid strong plasma and hospital performance

Analyst ratings

82%

of 11 ratings
Buy
81.8%
Hold
18.2%
Sell
0%

More HAE News

Nasdaq 13h
Haemonetics Corp Bottom Line Climbs In Q2

(RTTNews) - Haemonetics Corp (HAE) revealed a profit for its second quarter that Increases, from last year The company's bottom line came in at $38.68 million,...

Haemonetics Corp Bottom Line Climbs In Q2
TipRanks 17h
Haemonetics: Strong Financial Performance and Strategic Adjustments Drive Buy Rating

Needham analyst Michael Matson maintained a Buy rating on Haemonetics today and set a price target of $78.00. Meet Your ETF AI Analyst Discover how TipRanks' ET...

People also own

Based on the portfolios of people who own HAE. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.